Table 3.
Ceramides after Myriocin treatment
| Sphingolipid | Control (n=5) | Control + Myriocin (n=9) | Elastase (n=9) | Elastase + Myriocin (n=10) |
|---|---|---|---|---|
| Ceramide 16:0 |
30.01 ± 6.65 |
22.23 ± 7.95 |
41.04 ± 18.77 |
21.69 ± 4.91[] |
| Ceramide 18:0 |
3.13 ± 0.58 |
2.86 ± 0.75 |
4.00 ± 1.89 |
2.61 ± 0.60[] |
| Ceramide 20:0 |
1.94 ± 0.47 |
1.93 ± 0.43 |
2.73 ± 1.18 |
2.02 ± 0.43 |
| Ceramide 22:0 |
7.97 ± 1.67 |
7.99 ± 3.42 |
15.13 ± 7.96* |
9.11 ± 3.02[] |
| Ceramide 24:0 |
37.34 ± 9.00 |
33.24 ± 13.50 |
77.75 ± 44.65* |
39.72 ± 13.00[] |
| Ceramide 24:1 |
24.66 ± 7.60 |
17.33 ± 8.02 |
41.48 ± 20.83* |
19.44 ± 6.27[] |
| Dihydro Ceramide 18:0 |
0.38 ± 0.21 |
0.37 ± 0.20 |
0.70 ± 0.27* |
0.44 ± 0.17[] |
| Dihydro Ceramide 24:0 | 1.97 ± 1.18 | 1.83 ± 0.65 | 6.12 ± 3.94* | 3.42 ± 2.21[] |
BAL fluid was collected and processed using LCMS. Data are expressed as Mean + SEM in ng/ml BAL fluid. *p<0.05 when compared to Control. [] p<0.05 when compared to Elastase + Myriocin.